Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix

Urology

Volumn 83, Issue 5, 2014, Pages 1122-1128

  Crawford, E David ^a   Shore, Neal D ^b   Moul, Judd W ^c   Tombal, Bertrand ^d   Schröder, Fritz H ^e   Miller, Kurt ^f   Boccon Gibod, Laurent ^g   Malmberg, Anders ^h   Olesen, Tine Kold ^h   Persson, Bo Eric ^h   Klotz, Laurence ⁱ  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Carolina Urologic Research Center   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g BICHAT HOSPITAL   (France)

^h Ferring Pharmaceuticals AS   (Denmark)

ⁱ UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEGARELIX; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADVERSE OUTCOME; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HUMAN; INJECTION SITE REACTION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SWELLING;

CROSS-OVER STUDIES; DISEASE-FREE SURVIVAL; HUMANS; LEUPROLIDE; MALE; OLIGOPEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; TIME FACTORS;

EID: 84899476746     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2014.01.013     Document Type: Article

References (21)

1. L. Klotz Degarelix acetate for the treatment of prostate cancer Drugs Today (Barc) 45 2009 725 730
2. L. Klotz, L. Boccon-Gibod, and N.D. Shore et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer BJU Int 102 2008 1531 1538
3. H. van Poppel, and S. Nilsson Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 71 2008 1001 1006
4. B. Tombal, K. Miller, and L. Boccon-Gibod et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics Eur Urol 57 2010 836 842
5. F.H. Schroder, B. Tombal, and K. Miller et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study BJU Int 106 2010 182 187
6. E.D. Crawford, B. Tombal, and K. Miller et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer J Urol 186 2011 889 897
7. D. Kim, M. Woodroofe, and Y. Wu Testing for a change in the hazard rate with staggered entry Commun Stat - Theor Methods 33 2004 2041 2058
8. D. Oka, M. Shiba, and Y. Arai et al. Skin reactions to 3-month depot type of luteinizing hormone-releasing hormone agonist therapy JAMJ 49 2006 48 54
9. Sanofi-Aventis. Eligard 7.5 mg prescribing information 2007. Available at: http://products.sanofi.us/eligard/eligard.html#section-8.2. Accessed February 12, 2014.
10. W. Koechling, R. Hjortkjaer, and L.B. Tanko Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples Br J Clin Pharmacol 70 2010 580 587
11. M. Gittelman, P.J. Pommerville, and B.E. Persson et al. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America J Urol 180 2008 1986 1992
12. H. Van Poppel, B. Tombal, and J.J. de la Rosette et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker - results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer Eur Urol 54 2008 805 813
13. B. Tombal Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol 4 2005 14 19
14. J. Morote, J.P. Morin, and A. Orsola et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer Urology 69 2007 500 504
15. V. Bertaglia, M. Tucci, and C. Fiori et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer Clin Genitourin Cancer 11 2013 325 330 e321
16. S.G. Williams, G.M. Duchesne, J.L. Millar, and G.R. Pratt Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 60 2004 1082 1087
17. M. Hussain, C.M. Tangen, and C. Higano et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162) J Clin Oncol 24 2006 3984 3990
18. M. Hussain, B. Goldman, and C. Tangen et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916 J Clin Oncol 27 2009 2450 2456
19. M.J. Zelefsky, D.R. Gomez, and W.R. Polkinghorn et al. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes Int J Radiat Oncol Biol Phys 86 2013 529 533
20. P.C. Albertsen, L. Klotz, and B. Tombal et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist Eur Urol 65 2014 565 573
21. H.T. Hatoum, E.D. Crawford, and S.K. Nielsen et al. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer Expert Rev Pharmacoecon Outcomes Res 13 2013 261 270